NCT04634682 is a NA clinical trial of MYODM in Myotonic Dystrophy 1, sponsored by Myogem Health Company, S.L..

Who is sponsoring NCT04634682?

NCT04634682 is sponsored by Myogem Health Company, S.L..

What drugs are being tested in NCT04634682?

Interventions in NCT04634682: MYODM.

What condition does NCT04634682 study?

NCT04634682 studies Myotonic Dystrophy 1.

Is NCT04634682 still recruiting?

NCT04634682 is currently completed. Last updated 6 April 2022.

Last reviewed 2022-04-06 · How we verify

NCT04634682

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1

Completed NA Last updated 6 April 2022

What this trial tests

NA trial testing MYODM in Myotonic Dystrophy 1 in 30 participants. Completed in 3 December 2021.

Timeline

9 November 2020

Primary endpoint
15 November 2021

3 December 2021

Quick facts

Lead sponsor	Myogem Health Company, S.L.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	9 November 2020
Primary completion	15 November 2021
Estimated completion	3 December 2021
Sites	1 location across Spain

Drugs / interventions tested

MYODM

Conditions studied

Myotonic Dystrophy 1 — all drugs for Myotonic Dystrophy 1 →

Sponsor

Myogem Health Company, S.L.

Who can join

18 and older, any sex, with Myotonic Dystrophy 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether MYODM (formulated composition containing Theobroma cacao supplemented with caffeine (caffeine/theobromine ratio1/1.85, w/w) is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1) and improves the quality of life of these patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Myotonic dystrophy type 1 drug development: A pipeline toward the market.
Pascual-Gilabert M, López-Castel A, Artero R. · · 2021 · cited 39× · PMID 33798646 · DOI 10.1016/j.drudis.2021.03.024
Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective.
Kuntawala DH, Vitorino R, Cruz AC, Martins F, et al · · 2025 · cited 4× · PMID 40508159 · DOI 10.3390/ijms26115350

Verify or expand the search:

Other recruiting trials for Myotonic Dystrophy 1

Currently open trials in the same condition.

NCT07385443 — The Spanish National Registry for Myotonic Dystrophy Type 1 · recruiting
NCT06378216 — Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe] · recruiting
NCT03981575 — Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04634682 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Myogem Health Company, S.L.
Last refreshed: 6 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing